We report 7 cases of an indolent, variably myxoid tumor of the vocal cords, characterized by overt cellular atypia with large cells containing intranuclear and intracytoplasmic vacuoles, delicate curvilinear vessels, and sparse inflammatory infiltrate. Six patients were male, aged 15 to 65 years, and 1 patient was a 54-year-old female. All tumors were located in the superficial portion of the vocal cord. One patient suffered a recurrence that was completely resected; all patients with available follow-up data currently have no evidence of disease. The tumors contained alternating areas with myxoid stroma and more compacted regions with tumor cells organized in short fascicles, interwoven with delicate curvilinear vasculature. Overt cellular atypia with large cells containing intranuclear and intracytoplasmic vacuoles or resembling ganglion cells was present in all cases but mitoses and necrosis were absent. ALK immunostaining was positive in all cases, while most tumors were negative for smooth muscle actin. Targeted RNA-sequencing revealed an identical TIMP3::ALK fusion with exon 1 of TIMP3 gene being fused with exon 12 of ALK gene in all analyzable cases. For various reasons discussed, it remains unclear whether this tumor represents a mere subtype of IMT or a separate entity. Nevertheless, it is a morphologically distinct and diagnostically challenging lesion that needs to be recognized by surgical pathologists in order to prevent overdiagnosis in this clinically very delicate area.

Bioptical Laboratory Ltd Pilsen Czech Republic

Department of Diagnostic Pathology Japanese Red Cross Kochi Hospital Kochi Japan

Department of Pathology Charles University Faculty of Medicine in Pilsen Alej Svobody 80 323 00 Pilsen Czech Republic

Department of Pathology Regional Hospital Most Most Czech Republic

Institute of Pathology Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Institute of Pathology Friedrich Alexander University Erlangen Nürnberg University Hospital Erlangen Erlangen Germany

Zobrazit více v PubMed

WHO classification of tumours editorial board (2020) WHO classification of tumours of soft tissue and bone, 5th edn. IARC Press, Lyon

Yamamoto H, Yoshida A, Taguchi K et al (2016) ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology 69(1):72–83 PubMed

Antonescu CR, Suurmeijer AJ, Zhang L et al (2015) Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol 39(7):957–967 PubMed PMC

Pierry C, Pérot G, Karanian-Philippe M et al (2015) Polypoid laryngeal inflammatory myofibroblastic tumors: misleading lesions: description of six cases showing ALK overexpression. Am J Clin Pathol 144(3):511–516 PubMed

Coffin CM, Watterson J, Priest JR, Dehner LP (1995) Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 19(8):859–872 PubMed

Kerr DA, Thompson LDR, Tafe LJ et al (2021) Clinicopathologic and genomic characterization of inflammatory myofibroblastic tumors of the head and neck: highlighting a novel fusion and potential diagnostic pitfall. Am J Surg Pathol 45(12):1707–1719 PubMed

Meis JM, Enzinger FM (1991) Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol. 15(12):1146–1156 PubMed

Coffin CM, Humphrey PA, Dehner LP (1998) Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol 15(2):85–101 PubMed

Yorita K, Togashi Y, Nakagawa H et al (2019) Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: a potential diagnostic pitfall. Pathol Int 69(6):366–371 PubMed

Agaimy A, Baněčková M, Ihrler S et al (2021) ALK Rearrangements characterize 2 distinct types of salivary gland carcinomas: clinicopathologic and molecular analysis of 4 cases and literature review. Am J Surg Pathol 45(9):1166–1178 PubMed

Ptáková N, Miesbauerová M, Kosťun J et al (2018) Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors. Virchows Arch 473(5):583–590 PubMed

Agaimy A, Tögel L, Haller F, Zenk J, Hornung J, Märkl B (2020) YAP1-NUTM1 gene fusion in porocarcinoma of the external auditory canal. Head Neck Pathol 14(4):982–990 PubMed PMC

Coffin CM, Hornick JL, Fletcher CD (2007) Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31(4):509–520 PubMed

Eyden B (2004) Fibroblast phenotype plasticity: relevance for understanding heterogeneity in “fibroblastic” tumors. Ultrastruct Pathol 28(5–6):307–319 PubMed

Eyden B (2008) The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med 12(1):22–37 PubMed

Cao Z, Gao Q, Fu M, Ni N, Pei Y, Ou WB (2019) Anaplastic lymphoma kinase fusions: roles in cancer and therapeutic perspectives. Oncol Lett 17(2):2020–2030 PubMed

Gustafson S, Medeiros LJ, Kalhor N, Bueso-Ramos CE (2009) Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors. Ann Diagn Pathol 13(6):413–427 PubMed

Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14(13):4275–4283 PubMed PMC

Chou A, Fraser S, Toon CW et al (2015) A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 39(5):652–659 PubMed PMC

Janoueix-Lerosey I, Lequin D, Brugières L et al (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455(7215):967–970 PubMed

George RE, Sanda T, Hanna M et al (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455(7215):975–978 PubMed PMC

Piarulli G, Puls F, Wängberg B et al (2019) Gene fusion involving the insulin-like growth factor 1 receptor in an ALK-negative inflammatory myofibroblastic tumour. Histopathology 74(7):1098–1102 PubMed

Huang H (2018) Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase: a catalytic receptor with many faces. Int J Mol Sci 19(11):3448 PMC

Völker HU, Scheich M, Zettl A, Hagen R, Müller-Hermelink HK, Gattenlöhner S (2010) Laryngeal inflammatory myofibroblastic tumors: different clinical appearance and histomorphologic presentation of one entity. Head Neck 32(11):1573–1578 PubMed

Haimes JD, Stewart CJR, Kudlow BA et al (2017) Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1. Am J Surg Pathol 41(6):773–780 PubMed

Bennett JA, Nardi V, Rouzbahman M, Morales-Oyarvide V, Nielsen GP, Oliva E (2017) Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. Mod Pathol 30(10):1489–1503 PubMed

Devereaux KA, Fitzpatrick MB, Hartinger S, Jones C, Kunder CA, Longacre TA (2020) Pregnancy-associated inflammatory myofibroblastic tumors of the uterus are clinically distinct and highly enriched for TIMP3-ALK and THBS1-ALK fusions. Am J Surg Pathol 44(7):970–981 PubMed

Cheek EH, Fadra N, Jackson RA et al (2020) Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion. Hum Pathol 97:29–39 PubMed

Makhdoum S, Nardi V, Devereaux KA et al (2020) Inflammatory myofibroblastic tumors associated with the placenta: a series of 9 cases. Hum Pathol 106:62–73 PubMed

Val-Bernal JF, Martino M, Longarela MY (2020) Cellular myxoma of the vocal cord: a case report and review of the literature. Turk Patoloji Derg 36(1):77–81 PubMed

Sanfilippo R, Miceli R, Grosso F et al (2011) Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 18(3):720–725 PubMed

Gilg MM, Sunitsch S, Leitner L et al (2020) Tumor-associated mortality and prognostic factors in myxofibrosarcoma - a retrospective review of 109 patients. Orthop Traumatol Surg Res 106(6):1059–1065 PubMed

Yoshimoto M, Yamada Y, Ishihara S et al (2020) Comparative study of myxofibrosarcoma with undifferentiated pleomorphic sarcoma: histopathologic and clinicopathologic review. Am J Surg Pathol 44(1):87–97 PubMed

Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR (2004) Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 35(5):612–621 PubMed

Zhang B, Bai M, Tian R, Hao S (2021) Idiopathic and radiation-induced myxofibrosarcoma in the head and neck-case report and literature review. Chin Neurosurg J 7(1):48 PubMed PMC

Dell’Aversana Orabona G, Iaconetta G, Abbate V et al (2014) Head and neck myxofibrosarcoma: a case report and review of the literature. J Med Case Rep 8:468 PubMed PMC

Gugatschka M, Beham A, Stammberger H, Schmid C, Friedrich G (2010) First case of a myxofibrosarcoma of the vocal folds: case report and review of the literature. J Voice 24(3):374–376 PubMed

Cowan ML, Thompson LD, Leon ME, Bishop JA (2016) Low-Grade Fibromyxoid Sarcoma of the Head and Neck: A Clinicopathologic Series and Review of the Literature. Head Neck Pathol. 10(2):161–6 PubMed DOI

Lau PP, Lui PC, Lau GT, Yau DT, Cheung ET, Chan JK (2013) EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma. Am J Surg Pathol 37(5):734–738 PubMed

Mertens F, Fletcher CD, Antonescu CR et al (2005) Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest 85(3):408–415 PubMed

Panagopoulos I, Storlazzi CT, Fletcher CD et al (2004) The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Gene Chromosome Cancer 40(3):218–228

Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM (2009) Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 62(12):1127–1135 PubMed

Molecular pathology in diagnosis and prognostication of head and neck tumors